PL3021838T3 - Leczenie otyłości - Google Patents

Leczenie otyłości

Info

Publication number
PL3021838T3
PL3021838T3 PL14825724T PL14825724T PL3021838T3 PL 3021838 T3 PL3021838 T3 PL 3021838T3 PL 14825724 T PL14825724 T PL 14825724T PL 14825724 T PL14825724 T PL 14825724T PL 3021838 T3 PL3021838 T3 PL 3021838T3
Authority
PL
Poland
Prior art keywords
obesity
treatment
Prior art date
Application number
PL14825724T
Other languages
English (en)
Inventor
Moise A. Khayrallah
Gary Bream
Stephen E. Butts
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Sk Biopharmaceuticals Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Limited, Sk Biopharmaceuticals Co., Ltd filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of PL3021838T3 publication Critical patent/PL3021838T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL14825724T 2013-07-18 2014-07-18 Leczenie otyłości PL3021838T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361847593P 2013-07-18 2013-07-18
PCT/US2014/047186 WO2015010014A1 (en) 2013-07-18 2014-07-18 Treatment for obesity
EP14825724.9A EP3021838B1 (en) 2013-07-18 2014-07-18 Treatment for obesity

Publications (1)

Publication Number Publication Date
PL3021838T3 true PL3021838T3 (pl) 2021-03-08

Family

ID=52344067

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14825724T PL3021838T3 (pl) 2013-07-18 2014-07-18 Leczenie otyłości

Country Status (12)

Country Link
US (6) US9226910B2 (pl)
EP (1) EP3021838B1 (pl)
JP (2) JP6529495B2 (pl)
KR (1) KR102309836B1 (pl)
CN (2) CN105873576B (pl)
CA (1) CA2917702A1 (pl)
DK (1) DK3021838T3 (pl)
ES (1) ES2812586T3 (pl)
PL (1) PL3021838T3 (pl)
PT (1) PT3021838T (pl)
TW (1) TW201919605A (pl)
WO (1) WO2015010014A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102309836B1 (ko) * 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10661504B2 (en) * 2015-03-02 2020-05-26 Funfare, Llc Three dimensional printer and cartridge
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
EP4033068A1 (en) 2021-01-25 2022-07-27 Welltec A/S Downhole wireline tool string
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
WO2025098416A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于减肥的glp-1化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
CA2622696A1 (en) * 2007-11-05 2009-05-05 Diane Mcintosh Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
KR102173587B1 (ko) * 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
EP2543660A4 (en) * 2010-03-04 2014-04-30 Ajinomoto Kk PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9359290B2 (en) 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
KR102309836B1 (ko) * 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료

Also Published As

Publication number Publication date
US20150025136A1 (en) 2015-01-22
EP3021838B1 (en) 2020-05-27
JP6529495B2 (ja) 2019-06-12
CN110638804A (zh) 2020-01-03
CA2917702A1 (en) 2015-01-22
TW201919605A (zh) 2019-06-01
WO2015010014A1 (en) 2015-01-22
US20160081970A1 (en) 2016-03-24
US11497725B2 (en) 2022-11-15
PT3021838T (pt) 2020-09-01
US20210077450A1 (en) 2021-03-18
EP3021838A4 (en) 2017-01-18
DK3021838T3 (da) 2020-08-24
KR102309836B1 (ko) 2021-10-12
US12201601B2 (en) 2025-01-21
ES2812586T3 (es) 2021-03-17
US20230172896A1 (en) 2023-06-08
EP3021838A1 (en) 2016-05-25
US9226910B2 (en) 2016-01-05
JP2019089859A (ja) 2019-06-13
US20190099395A1 (en) 2019-04-04
KR20160032127A (ko) 2016-03-23
JP2016532679A (ja) 2016-10-20
JP6824315B2 (ja) 2021-02-03
CN105873576B (zh) 2019-07-19
US9649291B2 (en) 2017-05-16
US10105341B2 (en) 2018-10-23
US20170340596A1 (en) 2017-11-30
CN105873576A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
PL3021838T3 (pl) Leczenie otyłości
IL244869A0 (en) Device treatment
GB201300928D0 (en) Apparatus
GB2512025B (en) Surface treatment device
GB201302789D0 (en) Apparatus
GB201304872D0 (en) Treatment
GB201308440D0 (en) Therapeutic
GB201312419D0 (en) Manipulation treatment apparatus
GB201312517D0 (en) Apparatus
GB201310755D0 (en) Therapy
IL245463A0 (en) valve
GB2509779B (en) Splint
GB201318668D0 (en) Sonosensitive therapeutic
GB201307310D0 (en) Treatment
GB201316521D0 (en) Therapeutic apparatus
GB201311738D0 (en) Apparatus
GB201310529D0 (en) Traysealing apparatus
GB2509801B (en) Splint
GB201304811D0 (en) Novel treatment for hypertension
GB201300968D0 (en) Apparatus
GB201321115D0 (en) Treatment
GB201309238D0 (en) Treatment
PH22013000280U1 (en) Splint
GB201310661D0 (en) Splint
GB201322764D0 (en) Treating places